Nucleoside transport inhibitor, dipyridamole, induced myocardial protection following hemorrhagic shock in ex vivo perfused rat hearts

Journal of the Saudi Heart Association

Volumn 23, Issue 2, 2011, Pages 75-80

  Soliman, Mona ^a  

^a KING KHALID UNIVERSITY HOSPITAL   (Saudi Arabia)

Author keywords

Dipyridamole; Hemorrhage; Isolated hearts; Myocardial protection; Rat

Indexed keywords

BUFFER; DIPYRIDAMOLE; KREBS HENSELEIT BUFFER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD TRANSFUSION; CONTROLLED STUDY; EX VIVO STUDY; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HEART MUSCLE INJURY; HEART PERFUSION; HEART PROTECTION; HEMORRHAGIC SHOCK; IN VIVO STUDY; ISOLATED HEART; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RESUSCITATION;

EID: 79952620220     PISSN: 10167315     EISSN: 22125043     Source Type: Journal    
DOI: 10.1016/j.jsha.2011.01.004     Document Type: Article

References (17)

1. Amrani M., et al. Enhancement of low coronary reflow improves postischemic myocardial function. J. Thorac. Cardiovasc. Surg. 1992, 104:1375-1382.
2. Auchampach J., Gross G. Adenosine A1 receptors, KATP channels, and ischemic preconditioning in dogs. Am. J. Physiol. 1993, 264:H1327-H1336.
3. Bedetti G., et al. The beneficial effect of insulin, glucose, and dipyridamole on regional left ventricular function early after acute myocardial infarction. Int. J. Cardiol. 2005, 102(2):255-258.
4. Charo I.F., Taubman M.B. Chemokines in the pathogenesis of vascular disease. Circ. Res. 2004, 95(9):858-866.
5. Cohen M.V., et al. The effects of nitroglycerin on coronary collaterals and myocardial contractility. J. Clin. Invest. 1973, 52(11):2836-2847.
6. Crookes B.A., et al. Building a better fluid for emergency resuscitation of traumatic brain injury. J. Trauma 2004, 57(3):547-554.
7. Gokgoz L., et al. Dipyridamole induced myocardial recovery after global ischemia. Gen. Pharmacol. 1992, 23(3):435-437.
8. Gresele P., et al. Mechanism of the antiplatelet action of dipyridamole in whole blood: modulation of adenosine concentration and activity. Thromb. Haemost. 1986, 55(1):12-18.
9. Kattus A.A., Gregg D.E. Some determinants of coronary collateral blood flow in the open-chest dog. Circ. Res. 1959, 7(4):628-642.
10. Libby P., Theroux P. Pathophysiology of coronary artery disease. Circulation 2005, 111(25):3481-3488.
11. Lucarini A.R., et al. Activation of sympathetic tone during dipyridamole test. Chest 1992, 102(2):444-447.
12. Picano E., et al. Identification of viable myocardium by dipyridamole-induced improvement in regional left ventricular function assessed by echocardiography in myocardial infarction and comparison with thallium scintigraphy at rest. Am. J. Cardiol. 1992, 70(7):703-710.
13. Stahl L.D., Aversano T.R., Becker L.C. Selective enhancement of function of stunned myocardium by increased flow. Circulation 1986, 74(4):843-851.
14. Strauer B.E., et al. Pharmacologic myocardial protection during percutaneous transluminal coronary angioplasty by intracoronary application of dipyridamole: impact on hemodynamic function and left ventricular performance. J. Am. Coll. Cardiol. 1996, 28(5):1119-1126.
15. Verhoeven B.A., et al. Carotid atherosclerotic plaque characteristics are associated with microembolization during carotid endarterectomy and procedural outcome. Stroke 2005, 36(8):1735-1740.
16. Weyrich A.S., et al. Dipyridamole selectively inhibits inflammatory gene expression in platelet-monocyte aggregates. Circulation 2005, 111(5):633-642.
17. Wollner A., Wollner S., Smith J.B. Acting via A2 receptors, adenosine inhibits the upregulation of Mac-1 (Cd11b/CD18) expression on FMLP-stimulated neutrophils. Am. J. Respir. Cell Mol. Biol. 1993, 9(2):179-185.